


## TGFβRI-IN-4

Cat. No.:	HY-146780
CAS No.:	2421135-03-5
Molecular Formula:	C <sub>23</sub> H <sub>25</sub> F <sub>2</sub> N <sub>5</sub> O <sub>2</sub>
Molecular Weight:	441.47
Target:	TGF-β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC <sub>50</sub> s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model <sup>[1]</sup> .																						
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 44 nM (ALK5), 42.5 nM (NIH3T3) <sup>[1]</sup>																						
<b>In Vivo</b>	<p>TGFβRI-IN-4 (compound 15r) (60 mg/kg; PO; BID, for 21 days) efficiently suppresses tumor growth and tumor weight in tumor xenograft model<sup>[1]</sup>.</p> <p>TGFβRI-IN-4 (1 mg/kg and 10 mg/kg; IV and PO; single) exhibits good oral plasma exposure and excellent bioavailability<sup>[1]</sup>. Pharmacokinetic Parameters of TGFβRI-IN-4 in male Sprague-Dawley rats<sup>[1]</sup>.</p> <table border="1"> <thead> <tr> <th></th> <th>IV (1 mg/kg)</th> <th>PO (10 mg/kg)</th> </tr> </thead> <tbody> <tr> <td>T<sub>1/2</sub> (h)</td> <td>0.5</td> <td>1.8</td> </tr> <tr> <td>CL (L/h/kg)</td> <td>4.9</td> <td></td> </tr> <tr> <td>C<sub>max</sub> (ng/mL)</td> <td></td> <td>926.0</td> </tr> <tr> <td>V<sub>SS</sub> (L/kg)</td> <td>3.0</td> <td></td> </tr> <tr> <td>AUC<sub>0-24</sub> (ng/mL·h)</td> <td>195.2</td> <td>2351.2</td> </tr> <tr> <td>F (%)</td> <td></td> <td>120.5%</td> </tr> </tbody> </table>			IV (1 mg/kg)	PO (10 mg/kg)	T <sub>1/2</sub> (h)	0.5	1.8	CL (L/h/kg)	4.9		C <sub>max</sub> (ng/mL)		926.0	V <sub>SS</sub> (L/kg)	3.0		AUC <sub>0-24</sub> (ng/mL·h)	195.2	2351.2	F (%)		120.5%
	IV (1 mg/kg)	PO (10 mg/kg)																					
T <sub>1/2</sub> (h)	0.5	1.8																					
CL (L/h/kg)	4.9																						
C <sub>max</sub> (ng/mL)		926.0																					
V <sub>SS</sub> (L/kg)	3.0																						
AUC <sub>0-24</sub> (ng/mL·h)	195.2	2351.2																					
F (%)		120.5%																					
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.																						
Animal Model:	Female BALB/C mice (5-8 weeks; injected with CT26 cells) <sup>[1]</sup>																						
Dosage:	60 mg/kg																						
Administration:	PO; BID, for 21 days																						

Result:	Efficiently suppressed tumor growth (tumor growth inhibition = 65.7%) and tumor weight.
Animal Model:	Male BALB/C mice <sup>[1]</sup>
Dosage:	1 mg/kg and 10 mg/kg
Administration:	IV and PO; single (Pharmacokinetic Analysis)
Result:	Exhibited good oral plasma exposure and excellent bioavailability with AUC >2000 h·ng/mL and F > 80%, respectively.

## REFERENCES

[1]. Xu G, et al. Synthesis and biological evaluation of 4-(pyridin-4-oxyl)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor- $\beta$  type 1 receptor inhibitors. *Eur J Med Chem.* 2020;198:112354.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA